Back to Research Hub
Septerna, Inc.
SEPN
$31.01+0.60 (+1.97%)
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
StreetsValue research for Septerna, Inc. (SEPN)
Members get the full report for Septerna, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.